Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Epstein-Barr Virus Nuclear Antigen 1 (Ebna1) Increases the Expression Levels of Mdm2 and Mdm4 Genes in Hela Cells: A Review on Mdm2 and Mdm4 Roles in Cancer Publisher Pubmed



Hashemi SMA1 ; Alipour AH1, 2 ; Emamifar S1 ; Farhadi A3 ; Sarvari J1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Source: BMC Research Notes Published:2025


Abstract

Objective: Epstein-Barr virus nuclear antigen 1 (EBNA1) is a key viral protein expressed in all latency phases and EBV-associated tumors. It can modulate the expression of various host and viral genes. This study aimed to investigate the impact of EBNA1 on the expression levels of two cellular genes involved in p53 pathway regulation—MDM2 and MDM4—in HeLa cells. This investigation was conducted as part of our broader research on EBV-related oncogenic mechanisms. Results: HeLa cells were transfected with either an EBNA1-expressing plasmid or a control plasmid. Gene expression levels of MDM2 and MDM4 were analyzed using real-time PCR. The results demonstrated a statistically significant increase in MDM4 expression in EBNA1-transfected cells compared to controls (p = 0.028). Although MDM2 expression was also elevated, the difference was not statistically significant (p = 0.11). These findings suggest that EBNA1 may play a role in cervical cancer development by upregulating genes that inhibit p53 tumor suppressor activity. © The Author(s) 2025.